secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0000950103-25-007061
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics elects Timothy Coughlin to board at 2025 AGM; all proposals pass
--------------------------------------------------------------------------------

- Timothy Coughlin elected to board; CPA, former Neurocrine CFO, appointed audit committee chair.
- Binding votes: board max comp $2.3M, exec fixed $2.6M, variable $3.5M.
- Amendment to 2019 Equity Incentive Plan approved to increase authorized shares.
- Articles of association amended to raise conditional share capital for employee participation.
- All 12 shareholder proposals, including director elections and say-on-pay, approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/0000950103-25-007061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/dp229762_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-007061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer